GSK’s Shingrix Receives NMPA’s Approval for the Prevention of Shingles in China

Shots:

• The approval follows P-III ZOE-50 and ZOE-70 studies assessing Shingrix in 38,000 patients with shingles (herpes zoster) aged ≥ 50yrs.
• The P-III ZOE-50 and ZOE-70 studies demonstrated efficacy >90% in all age group and showed sustained efficacy over a follow period of 4yrs.
• Shingrix (IM) is a herpes zoster vaccine, administered in two doses and is a combination of an antigen, glycoprotein E, an adjuvant system, AS01B, currently available in the US, EU, Canada, Japan and Australia

Click here to read full press release/ article | Ref: GSK | Image: CNBC